These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Molecular Mechanism of Betaine on Hepatic Lipid Metabolism: Inhibition of Forkhead Box O1 (FoxO1) Binding to Peroxisome Proliferator-Activated Receptor Gamma (PPARγ). Kim DH; Lee B; Kim MJ; Park MH; An HJ; Lee EK; Chung KW; Park JW; Yu BP; Choi JS; Chung HY J Agric Food Chem; 2016 Sep; 64(36):6819-25. PubMed ID: 27546313 [TBL] [Abstract][Full Text] [Related]
23. MicroRNA-21 regulates hepatic glucose metabolism by targeting FOXO1. Luo A; Yan H; Liang J; Du C; Zhao X; Sun L; Chen Y Gene; 2017 Sep; 627():194-201. PubMed ID: 28627440 [TBL] [Abstract][Full Text] [Related]
24. S100A11 Promotes Liver Steatosis via FOXO1-Mediated Autophagy and Lipogenesis. Zhang L; Zhang Z; Li C; Zhu T; Gao J; Zhou H; Zheng Y; Chang Q; Wang M; Wu J; Ran L; Wu Y; Miao H; Zou X; Liang B Cell Mol Gastroenterol Hepatol; 2021; 11(3):697-724. PubMed ID: 33075563 [TBL] [Abstract][Full Text] [Related]
26. Mechanism of Lipid Accumulation through PAR2 Signaling in Diabetic Male Mice. Kim DH; Kim YR; Bang E; Ha S; Noh SG; Kim BM; Jeong SH; Jung HJ; Lee JY; Chung HY Endocrinol Metab (Seoul); 2021 Feb; 36(1):171-184. PubMed ID: 33677938 [TBL] [Abstract][Full Text] [Related]
27. FOXO1 involvement in insulin resistance-related pro-inflammatory cytokine production in hepatocytes. Miao H; Zhang Y; Lu Z; Liu Q; Gan L Inflamm Res; 2012 Apr; 61(4):349-58. PubMed ID: 22223069 [TBL] [Abstract][Full Text] [Related]
28. Hepatic CREBZF couples insulin to lipogenesis by inhibiting insig activity and contributes to hepatic steatosis in diet-induced insulin-resistant mice. Zhang F; Hu Z; Li G; Huo S; Ma F; Cui A; Xue Y; Han Y; Gong Q; Gao J; Bian H; Meng Z; Wu H; Long G; Tan Y; Zhang Y; Lin X; Gao X; Xu A; Li Y Hepatology; 2018 Oct; 68(4):1361-1375. PubMed ID: 29637572 [TBL] [Abstract][Full Text] [Related]
29. Insulin regulates liver metabolism in vivo in the absence of hepatic Akt and Foxo1. Lu M; Wan M; Leavens KF; Chu Q; Monks BR; Fernandez S; Ahima RS; Ueki K; Kahn CR; Birnbaum MJ Nat Med; 2012 Feb; 18(3):388-95. PubMed ID: 22344295 [TBL] [Abstract][Full Text] [Related]
30. Hepatic mTORC2 activates glycolysis and lipogenesis through Akt, glucokinase, and SREBP1c. Hagiwara A; Cornu M; Cybulski N; Polak P; Betz C; Trapani F; Terracciano L; Heim MH; Rüegg MA; Hall MN Cell Metab; 2012 May; 15(5):725-38. PubMed ID: 22521878 [TBL] [Abstract][Full Text] [Related]
31. Upregulation of lncRNA MEG3 promotes hepatic insulin resistance via increasing FoxO1 expression. Zhu X; Wu YB; Zhou J; Kang DM Biochem Biophys Res Commun; 2016 Jan; 469(2):319-25. PubMed ID: 26603935 [TBL] [Abstract][Full Text] [Related]
32. NFE2 Induces miR-423-5p to Promote Gluconeogenesis and Hyperglycemia by Repressing the Hepatic FAM3A-ATP-Akt Pathway. Yang W; Wang J; Chen Z; Chen J; Meng Y; Chen L; Chang Y; Geng B; Sun L; Dou L; Li J; Guan Y; Cui Q; Yang J Diabetes; 2017 Jul; 66(7):1819-1832. PubMed ID: 28411267 [TBL] [Abstract][Full Text] [Related]
33. Liver-specific overexpression of pancreatic-derived factor (PANDER) induces fasting hyperglycemia in mice. Wilson CG; Schupp M; Burkhardt BR; Wu J; Young RA; Wolf BA Endocrinology; 2010 Nov; 151(11):5174-84. PubMed ID: 20844005 [TBL] [Abstract][Full Text] [Related]
34. Dual role of transcription factor FoxO1 in controlling hepatic insulin sensitivity and lipid metabolism. Matsumoto M; Han S; Kitamura T; Accili D J Clin Invest; 2006 Sep; 116(9):2464-72. PubMed ID: 16906224 [TBL] [Abstract][Full Text] [Related]
35. Acute exercise reduces hepatic glucose production through inhibition of the Foxo1/HNF-4alpha pathway in insulin resistant mice. De Souza CT; Frederico MJ; da Luz G; Cintra DE; Ropelle ER; Pauli JR; Velloso LA J Physiol; 2010 Jun; 588(Pt 12):2239-53. PubMed ID: 20421289 [TBL] [Abstract][Full Text] [Related]
36. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Svegliati-Baroni G; Saccomanno S; Rychlicki C; Agostinelli L; De Minicis S; Candelaresi C; Faraci G; Pacetti D; Vivarelli M; Nicolini D; Garelli P; Casini A; Manco M; Mingrone G; Risaliti A; Frega GN; Benedetti A; Gastaldelli A Liver Int; 2011 Oct; 31(9):1285-97. PubMed ID: 21745271 [TBL] [Abstract][Full Text] [Related]
37. GdCl3 reduces hyperglycaemia through Akt/FoxO1-induced suppression of hepatic gluconeogenesis in Type 2 diabetic mice. Wang Q; Wang N; Dong M; Chen F; Li Z; Chen Y Clin Sci (Lond); 2014 Jul; 127(2):91-100. PubMed ID: 24444370 [TBL] [Abstract][Full Text] [Related]
38. BMI-related progression of atypical PKC-dependent aberrations in insulin signaling through IRS-1, Akt, FoxO1 and PGC-1α in livers of obese and type 2 diabetic humans. Sajan MP; Ivey RA; Farese RV Metabolism; 2015 Nov; 64(11):1454-65. PubMed ID: 26386696 [TBL] [Abstract][Full Text] [Related]
39. Identification of Akt-independent regulation of hepatic lipogenesis by mammalian target of rapamycin (mTOR) complex 2. Yuan M; Pino E; Wu L; Kacergis M; Soukas AA J Biol Chem; 2012 Aug; 287(35):29579-88. PubMed ID: 22773877 [TBL] [Abstract][Full Text] [Related]
40. FoxO1 as a double-edged sword in the pancreas: analysis of pancreas- and β-cell-specific FoxO1 knockout mice. Kobayashi M; Kikuchi O; Sasaki T; Kim HJ; Yokota-Hashimoto H; Lee YS; Amano K; Kitazumi T; Susanti VY; Kitamura YI; Kitamura T Am J Physiol Endocrinol Metab; 2012 Mar; 302(5):E603-13. PubMed ID: 22215655 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]